It addresses how manufacturers can integrate dosage-form–specific GMP principles (including tablet manufacturing, capsule GMP, and sterile injectables) into a robust pharmaceutical quality system suitable for combination products. Regulatory considerations from FDA, EMA, MHRA, PIC/S, WHO, and ICH serve as the foundations for this comprehensive tutorial.

Step 1: Define Product Classification and Applicable GMP Frameworks

The initial step in managing GMP compliance for wearable injectors and on-body delivery systems is the clear classification of the product. These are combination products, consisting of a drug component (e.g., a parenteral solution or solid oral dosage form) integrated with a medical device component (the wearable injector mechanism). This classification determines the applicable GMP requirements and quality standards to be followed.

• Drug Component: The drug within these combination products may be a sterile injectable solution, a semi-solid formulation, or even solid oral tablets or capsules loaded into the device reservoir or cartridge.
• Device Component: The medical device includes electronic or mechanical delivery systems, sensors, actuators, and software to administer the dose on-body reliably.

As the product straddles pharmaceutical and medical device regulations, multiple GMP and quality frameworks apply including:

• Pharmaceutical GMP regulations—21 CFR Parts 210 and 211 (FDA), EU GMP for medicinal products including EU GMP Volume 4 and Annex 15 on qualification and validation.
• Device quality standards such as ISO 13485 and applicable MDR (EU) or FDA Quality System Regulation (QSR) for devices.
• ICH Q7 (API GMP) and ICH Q8-Q10 for pharmaceutical quality systems and development.
• PIC/S guidance for sterile and non-sterile manufacturing.

Several regulatory agencies emphasize the establishment of an integrated quality system to address both drug product GMP and device requirements. The complexity of these combination products means early engagement with regulatory bodies to define expectations is advisable to mitigate compliance gaps.

Step 2: Risk Assessment and ICH Q9 Application for Combination Products

Wearable injectors and on-body systems introduce new risks not typical of traditional dosage forms. Thorough risk assessment is critical to establish a control strategy addressing both drug product quality and device performance. ICH Q9 Quality Risk Management principles offer a structured, stepwise approach to identify, evaluate, and control risks.

Key risk elements to consider include:

• Drug Stability and Compatibility: Evaluate physicochemical stability and potential interactions between the drug payload and device materials, including contacts with plastics, elastomers, adhesives, and electronic components.
• Sterility and Particulate Control: Explore risks of contamination during fill-finish and device assembly, particularly for sterile injectables. On-body systems often require aseptic processing combined with subsequent assembly in controlled environments.
• Dose Accuracy and Delivery Reliability: Mechanical or electronic failures can cause under- or overdosing. Risk evaluation should include software reliability and human factors impacting device usability.
• Packaging and Transport Conditions: On-body devices must maintain integrity through shipping and patient wear-time, requiring assessment of temperature, moisture, and mechanical stress impact on both drug and device components.

The outcome of the risk assessment dictates the GMP controls, including process validation, cleaning validation for both drug and device components, supplier qualification, and environmental monitoring tailored for sensitive combination products.

Step 3: Integrating Dosage-Form–Specific GMP into Combination Product Manufacturing

Manufacturers must harmonize GMP principles for traditional dosage forms with device manufacturing controls. This involves adopting or adapting processes from tablet manufacturing, capsule GMP, sterile injectable production, and even inhalation product handling, depending on the nature of the drug payload. The following sub-steps outline this integration:

A. Drug Component Manufacturing

• Solid Oral Dosage Form Handling: When solid oral dosage forms (e.g., tablets or capsules) are loaded into wearable delivery devices, compliance with standard GMP requirements for powder handling, granulation, compression, and capsule filling apply. This includes control of cross-contamination, blend uniformity, and mechanical integrity.
• Sterile Injectable Preparation: For parenteral payloads, aseptic processing per 21 CFR 211 Subpart E or EU GMP Annex 1 is critical. These sterile fills may be performed off-site or in controlled cleanroom suites integrated with device assembly.
• Topical and Semi-Solid Formulations: If topical or semi-solid drugs are loaded, manufacturers must ensure appropriate environmental and cleaning controls in mixing and filling, referencing topical GMP and container closure integrity standards.

B. Device Manufacturing and Assembly

• Implement robust device manufacturing controls including component traceability, material specifications, biocompatibility verification, and software validation for electronic systems.
• Define cleanroom requirements or controlled environments for device assembly if the device interacts directly with sterile drug products.
• Integrate component inspections and functional testing to ensure dosing accuracy and device performance meet specifications before final packaging.

C. Combined Process Controls

• Develop validated processes that incorporate drug packaging into/on the device in a way compatible with drug stability and GMP controls.
• User requirements and human factors engineering must be validated and documented to confirm patient usability and safety.
• Establish cleaning and sterilization methods for reusable device components or single-use devices per applicable GMP standards and regulatory guidelines.

Step 4: Validation and Qualification Strategies for Wearable Injectors

Validation efforts must extend beyond traditional production processes to incorporate device-specific complexities. Qualification of equipment, utilities, and facilities must cover both pharmaceutical and device manufacturing and assembly. Key points include:

• Process Validation: Validate individual drug manufacturing steps (e.g., filling, lyophilization, coating) alongside device assembly steps. Process simulations or media fills should consider the combined product’s unique characteristics.
• Cleaning Validation: Establish validated cleaning procedures for shared equipment considering all drug forms used throughout production, ensuring no carryover or incompatibilities, particularly since device surfaces might be sensitive to cleaning agents.
• Analytical Method Validation: Validate analytical methods for drug potency, purity, and release must reflect the combined dosage form and delivery device matrix.
• Software and Electronic Validation: For devices with programmable components, software validation per FDA guidance on medical device software and EU MDR requirements must be completed. This is critical to ensure reliability of dose administration and data capture.
• Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ): These stages apply for all manufacturing and assembly equipment and cleanroom environments, ensuring controlled and reproducible operations.

Additionally, periodic requalification is required based on risk management outputs and change control procedures.

Step 5: Documentation, Quality Systems, and Regulatory Submissions

A strong documentation system is fundamental to demonstrate GMP compliance for wearable injectors and on-body delivery systems. This system should encompass all aspects of drug and device manufacturing, control, and distribution:

• Batch Records: Comprehensive batch production and control records must capture both pharmaceutical and device manufacturing parameters, including in-process checks and deviations.
• Device Master File and Design History File: Device documentation must demonstrate design controls, risk assessments, and verification tests consistent with medical device regulations.
• Quality Agreements: When drug components and devices are manufactured by separate sites or suppliers, establish formal quality agreements clarifying GMP responsibilities.
• Change Control: Robust change management addressing the interplay between drug formulation changes and device modifications is essential to maintain product integrity.
• Regulatory Submissions: Regulatory dossiers (e.g., FDA 510(k), PMA, or EMA MAA submissions) must integrate drug and device data, including manufacturing process descriptions, validation reports, and risk management files.

Manufacturers should leverage available guidance such as the FDA’s Current Good Manufacturing Practice Requirements for Combination Products, as well as EMA guidelines on drug-device combination products, to structure their submissions and quality systems.

Step 6: Handling Post-Market Requirements and Inspection Readiness

Once wearable injectors and on-body delivery systems reach the market, post-approval GMP compliance entails ongoing vigilance and continuous improvement. Considerations include:

• Pharmacovigilance and Device Vigilance Coordination: Adverse event reporting must integrate signals from both drug safety and medical device event monitoring.
• Periodic Product Quality Review: Incorporate data from both pharmaceutical and device manufacturing to identify trends and take corrective actions.
• Supply Chain and Serialization: Due to complex component sourcing, GMP-compliant supplier qualification, and traceability processes are critical.
• Inspection Preparation: Companies should be prepared for combined regulatory inspections assessing both drug GMP and device QSR compliance. Internal audits must focus on integrated quality system effectiveness and regulatory adherence.

Regulators such as the MHRA provide combined GMP and medical device inspection guidance for these innovative products. Implementing a mature quality management system that reflects the unique demands of combination products ensures readiness for regulatory scrutiny.

Conclusion and Recommendations for Pharma Professionals

Wearable injectors and on-body delivery systems represent cutting-edge pharmaceutical dosage forms combining parenteral, solid oral, topical, or inhalation drug formulations with complex delivery devices. Navigating the evolving GMP challenges requires an integrated approach adopting best practices from pharmaceutical GMP and medical device quality systems.

Key takeaways for pharmaceutical professionals, clinical operations, regulatory affairs, and medical affairs teams include:

• Early and clear product classification to determine applicable GMP frameworks.
• Comprehensive risk assessment following ICH Q9 principles that capture drug-device interface risks.
• Harmonized manufacturing controls blending compliance with tablet manufacturing, capsule GMP, sterile injectable production, and device assembly processes.
• Extensive validation and qualification covering pharmaceutical and device aspects, including software validation.
• Robust documentation and integrated quality systems supporting regulatory submissions and ongoing compliance.
• Proactive post-market quality and regulatory vigilance tailored to combination product complexity.

By following these step-by-step GMP practices, pharmaceutical manufacturers in the US, UK, and EU can confidently develop, produce, control, and supply wearable injectors and on-body delivery systems meeting stringent regulatory expectations and ultimately delivering safe, effective therapies to patients.